2009

1. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

   Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812